A Phase II trial of bortezomib in combination with docetaxel in recurrent and/or metastatic HNSCC was well-tolerated and demonstrated better therapeutic response in tumors expressing lower levels of NF-κB associated genes [219]. The gene discussed is NFKB1; the disease is head and neck squamous cell carcinoma.